1. Home
  2. SUPN vs DFIN Comparison

SUPN vs DFIN Comparison

Compare SUPN & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$51.66

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Donnelley Financial Solutions Inc.

DFIN

Donnelley Financial Solutions Inc.

HOLD

Current Price

$46.31

Market Cap

1.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUPN
DFIN
Founded
2005
1983
Country
United States
United States
Employees
N/A
1800
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
1.2B
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
SUPN
DFIN
Price
$51.66
$46.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$61.60
$63.50
AVG Volume (30 Days)
636.6K
267.6K
Earning Date
11-04-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.12
Revenue
$681,539,000.00
$750,800,000.00
Revenue This Year
$8.32
N/A
Revenue Next Year
$23.36
$4.20
P/E Ratio
N/A
$41.41
Revenue Growth
4.54
N/A
52 Week Low
$29.16
$37.80
52 Week High
$57.65
$69.93

Technical Indicators

Market Signals
Indicator
SUPN
DFIN
Relative Strength Index (RSI) 67.82 47.71
Support Level $51.01 $45.72
Resistance Level $52.30 $46.57
Average True Range (ATR) 1.49 1.17
MACD 0.65 0.12
Stochastic Oscillator 89.77 69.26

Price Performance

Historical Comparison
SUPN
DFIN

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About DFIN Donnelley Financial Solutions Inc.

Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.

Share on Social Networks: